Monoclonal Gammopathy of Undetermined Significance
Wilson I. GonsalvesDivision of Hematology, Mayo Clinic, Rochester, Minnesota (W.I.G., S.V.R.)S. Vincent RajkumarDivision of Hematology, Mayo Clinic, Rochester, Minnesota (W.I.G., S.V.R.)
2022en
ABI
Abstract
Monoclonal gammopathy of undetermined significance (MGUS) is of considerable clinical importance to primary care physicians given its high prevalence in the general population. MGUS has a variable but lifelong risk for progression to hematologic cancer, such as multiple myeloma, Waldenström macroglobulinemia, or light-chain amyloidosis. In addition, MGUS has been associated with several nonmalignant yet symptomatic disorders that require therapy directed toward eliminating the monoclonal gammopathy. Thus, it is important not only to understand the essentials of diagnosing and monitoring patients with MGUS but also to recognize when to refer patients with MGUS to a specialist.
Identifiers
Citations and references
Cited by 20 references